- Trial Phase
- Phase 2/3 (completed)
- Time to Market
- Potential BLA submission Q4 2026 with possible FDA approval in 2H 2027; if FDA requires additional OS data, timeline extends by 2-4 years
- Why 7/10
- The next hard, dated catalyst is the FDA pre-BLA meeting expected in early August 2026 (~1 month away), where Compass will seek alignment on a regulatory pathway for tovecimig's BLA submission in second-line biliary tract cancer. This binary outcome — FDA alignment vs. a request for more data — will determine whether a BLA can be filed in Q4 2026. Tovecimig is the company's lead and primary value driver, making this a high-concentration event.
Watch for the FDA pre-BLA meeting outcome in August 2026. Positive alignment (FDA accepts the PFS/ORR data with an argument for crossover-confounded OS) would clear the path for a Q4 2026 BLA filing and potential approval in 2H 2027, likely driving a sharp recovery from ~$2.18. Negative feedback (FDA requires a confirmatory OS trial) would severely delay approval and could push the stock below its $1.61 52-week low. The ~$195M cash runway into 2028 provides a long enough cushion even with delays.
Price Chart
Executive Summary
Tovecimig (CTX-009) is Compass Therapeutics' lead drug candidate — a bispecific antibody that starves tumors by blocking two blood-vessel growth pathways (DLL4 and VEGF-A). In the Phase 2/3 COMPANION-002 trial for second-line biliary tract cancer (a rare, aggressive cancer with few treatment options), it met its primary endpoint (response rate) and showed a 56% reduction in disease progression risk. However, it failed to improve overall survival — a crucial metric — due to a high crossover rate that scrambled the data. The stock crashed 63% on that news in April 2026, falling from ~$5 to ~$1.84. The company now plans a pivotal FDA pre-BLA meeting in August 2026 to determine whether regulators will accept the data package for a BLA submission. The stock trades at ~$2.18 with a Strong Buy analyst consensus and ~304% implied upside, but the binary risk of the FDA meeting outcome makes this a high-stakes, asymmetric bet.
How It Works
Tovecimig is a bispecific antibody — a Y-shaped protein designed to grab onto two different targets at once. It simultaneously blocks two signaling pathways (DLL4 and VEGF-A) that tumors rely on to grow new blood vessels (angiogenesis). By cutting off the tumor's blood supply from two angles at the same time, it starves the cancer more effectively than blocking either pathway alone. It's administered by IV infusion.
Trial Status
The pivotal COMPANION-002 Phase 2/3 trial (NCT05506943, n=168) has been completed. Top-line results: met primary endpoint (ORR 18% vs 5.3%, p=0.0228) and key secondary PFS endpoint (median 4.7 vs 2.6 months, HR=0.44, p<0.0001 — a 56% risk reduction). However, the OS secondary endpoint was missed (8.9 vs 9.4 months, HR=1.05, p=0.78), confounded by 54% crossover from control to active arm. A Phase 2 trial in colorectal cancer (COMPANION-003) has also completed. An investigator-sponsored front-line BTC trial is dosing patients. The company received FDA Fast Track Designation (April 2024) and Orphan Drug Designation (April 2026).
The Two-Sided Case
Upcoming Catalysts
- FDA pre-BLA meeting expected in early August 2026 — the single most important near-term catalyst determining whether BLA submission is viable
- BLA submission target: Q4 2026 (contingent on positive FDA meeting outcome)
- Potential FDA approval decision: 2H 2027 (if BLA filed and accepted)
- ASCO 2026 data presentation for pipeline candidate CTX-8371 (PD-1 x PD-L1 bispecific)
- Initial Phase 1 data for CTX-10726 (DLL4 x VEGF-A for other indications) expected Q4 2026
- Investigator-sponsored front-line BTC trial (tovecimig + Gem/Cis/Durva) ongoing
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Compass Therapeutics, Inc. 8-K CMPX ·Originating report